Treatment of Kratom Withdrawal
Treat kratom withdrawal with buprenorphine/naloxone using a similar approach to opioid withdrawal management, as kratom's active alkaloids (mitragynine and 7-hydroxymitragynine) act as partial mu-opioid receptor agonists and produce an opioid-like withdrawal syndrome.
Primary Treatment Approach
Buprenorphine/Naloxone as First-Line Therapy
The evidence consistently supports buprenorphine/naloxone as the most effective pharmacological treatment for kratom withdrawal 1, 2, 3, 4, 5. This makes physiological sense given that kratom's alkaloids function as partial opioid agonists, creating a withdrawal syndrome that responds to opioid receptor modulation.
Key clinical findings from case series:
- Buprenorphine induction can safely occur as early as 8 hours after last kratom use 4
- Maintenance dosing ranges from 2-24 mg daily, similar to opioid use disorder treatment 3, 4
- Higher doses (up to 24 mg daily in divided doses) may be needed for prolonged withdrawal symptoms or co-occurring pain 4
Induction Protocol
Assess withdrawal severity using the Clinical Opiate Withdrawal Scale (COWS):
- Wait until patient demonstrates objective withdrawal signs (COWS ≥8 preferred)
- Unlike traditional opioids, kratom withdrawal may allow earlier induction (8+ hours after last use) 4
- Start with buprenorphine 2-8 mg sublingual based on withdrawal severity 3
- Reassess after 30-60 minutes and titrate as needed
Critical timing consideration: The risk of precipitated withdrawal appears lower with kratom compared to traditional opioids, but still confirm active withdrawal before initiating buprenorphine 4.
Symptomatic Management Options
While no kratom-specific guidelines exist, extrapolating from opioid withdrawal management 6:
Non-Opioid Adjunctive Therapies
For patients with mild withdrawal or as adjuncts to buprenorphine:
- α2-adrenergic agonists: Clonidine or lofexidine for autonomic symptoms (ensure patient is not hypotensive)
- Antiemetics: Promethazine or ondansetron for nausea/vomiting
- Benzodiazepines: For anxiety, muscle cramps, and catecholamine-mediated symptoms
- Antidiarrheals: Loperamide for gastrointestinal symptoms
These agents address specific withdrawal symptoms but are less effective than buprenorphine for overall withdrawal management and relapse prevention 6.
Maintenance and Relapse Prevention
Kratom use disorder carries high relapse risk 2, making maintenance therapy critical:
Duration of Treatment
- Short-term medically managed withdrawal: 3-7 days of buprenorphine with taper 3
- However, long-term maintenance is strongly recommended given high relapse rates 1, 2, 4
- Maintenance dosing typically 8-16 mg daily, adjusted based on withdrawal symptoms and cravings 4
Monitoring Considerations
- Urine drug screening for kratom alkaloids should be available for facilities treating kratom dependence 4
- Standard opioid immunoassays will NOT detect kratom alkaloids
- Specialized testing for mitragynine and 7-hydroxymitragynine is required
Special Populations and Complications
Polysubstance Use
Patients using kratom alongside other substances may require:
- Higher buprenorphine doses (up to 24 mg daily) 4
- Higher levels of care (residential treatment)
- More intensive monitoring
Prolonged Withdrawal Symptoms
Some patients report continued withdrawal symptoms despite buprenorphine treatment 4. Management strategies:
- Consider multiple daily dosing (e.g., 8 mg TID rather than 24 mg once daily)
- Extend duration of maintenance therapy
- Address co-occurring pain or psychiatric conditions
Critical Pitfalls to Avoid
Don't assume kratom withdrawal is benign: While not life-threatening, it produces significant distress and high relapse risk 2
Don't use standard opioid drug screens: They won't detect kratom alkaloids; specialized testing is needed 4
Don't undertaper too quickly: Kratom dependence requires similar maintenance duration as traditional opioid use disorder 1, 2
Don't dismiss patient reports of kratom use: Prevalence is approximately 9.1% in some populations 7, and many patients use it for self-medication of pain, anxiety, or opioid withdrawal 7, 8
Alternative Considerations
Naltrexone has been reported in isolated cases 1 but lacks the immediate withdrawal relief that buprenorphine provides. It may be considered for highly motivated patients after completing medically managed withdrawal.
Methadone has been used in rare cases 1 but is impractical given regulatory restrictions requiring opioid treatment program enrollment.
Disposition and Follow-up
- Arrange addiction medicine or substance use disorder treatment follow-up before discharge
- Provide naloxone kit and overdose prevention education (risk of relapse to more potent opioids)
- Consider referral to residential treatment for severe dependence or polysubstance use 3
- Screen for hepatitis C, HIV, and address reproductive health 6
The indication for medications for opioid use disorder should be extended to moderate-to-severe kratom use disorder 1, as the pharmacological profile and clinical presentation warrant similar treatment approaches.